SCHEMBL356767

SCHEMBL356767

CCCc1noc(N2CCC(n3cc(F)c4c(Cl)ncnc43)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.41
EIF2AK3 Q9NZJ5 2/20 0.30
RET P07949 1/20 0.30
NEK7 Q8TDX7 1/20 0.30
SCN9A Q15858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369097 0.83 GPR119 (0.40) GPR119EIF2AK3RETNEK7
SCHEMBL355771 0.83 GPR119 (0.49) GPR119
SCHEMBL356620 0.79 GPR119 (0.45) GPR119
SCHEMBL10172614 0.78 GPR119 (0.42) GPR119NEK7SCN9A
SCHEMBL10140674 0.77 ADK (0.34) EIF2AK3RETNEK7
Hydrochloric Acid SCHEMBL357737 0.77 GPR119 (0.40) GPR119NEK7SCN9A
SCHEMBL10171960 0.76 GPR119 (0.48) GPR119NEK7SCN9A
SCHEMBL10172613 0.75 GPR119 (0.39) GPR119NEK7SCN9A
SCHEMBL369095 0.75 GPR119 (0.32) GPR119EIF2AK3RETNEK7
SCHEMBL356277 0.74 GPR119 (0.32) GPR119EIF2AK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
WO-2011145718-A1 NOVEL PYRROLO[2,3-D]PYRIMIDINE COMPOUND 田辺三菱製薬株式会社 (JP) 2011-11-24 WO disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 GPR119 1/4885EIF2AK3 3294/4885RET 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.